LB PHARMACEUTICALS INC — Director's Dealing 2025

Sep 11, 2025

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: LB PHARMACEUTICALS INC (LBRX)
CIK: 0001691082
Period of Report: 2025-09-10

Reporting Person: Deep Track Biotechnology Master Fund, Ltd. (N/A)
Reporting Person: Deep Track Capital, LP (10% Owner)
Reporting Person: KROIN DAVID (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series C Preferred Stock	$		Common Stock (686138)		Direct

Footnotes

F1: Each share of Series C Preferred Stock is convertible at anytime at the option of the holder, without payment of additional consideration, into Common Stock and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering, the Series C Preferred Stock will convert automatically at a conversion ratio that is dependent upon the initial price per share to the public in the Issuer's initial public offering.

F2: Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.